Polo-like Kinase 1 inhibition as a therapeutic approach to selectively target BRCA1-deficient cancer cells by synthetic lethality induction.

CONCLUSIONS: We uncovered an unforeseen addiction of BRCA1-deficient cancer cells to PLK1 expression which provides a new mean to exploit the therapeutic potential of PLK1 inhibitors in clinical trials, by generating stratification schemes that consider this molecular trait in patients cohorts.
PMID: 30890549 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 18, 2019 Category: Cancer & Oncology Authors: Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, García IA, Racca AC, Rodriguez-Berdini L, Angiolini V, Guantay L, Villafañez F, Federico MB, Rodríguez-Baili MC, Caputto BL, Drewes G, Madauss KP, Gloger I, Fernandez E, Gil GA, Boc Tags: Clin Cancer Res Source Type: research